#### **REVIEW**



# **Lignans from** *Sambucus williamsii* **Protect Bone Via Microbiome**

**Hui‑Hui Xiao1,2,3 · Daniel Kam‑Wah Mok1,2,3 · Xin‑Sheng Yao4 · Man‑Sau Wong1,2,3**

Accepted: 20 August 2024 / Published online: 5 September 2024 © The Author(s) 2024

#### **Abstract**

**Purpose of Review** Traditional Chinese Medicine has a unique system to diagnose and treat bone diseases with symptoms similar to those of osteoporosis. *Sambucus williamsii* Hance (SWH), a folk medicine in northern part of China for fractures healing and pain alleviation, has been demonstrated to exert bone anabolic efects in ovariectomized (OVX) rat and mice models in our previous studies. Lignans were identifed to be the main bioactive fractions of SWH. However, pharmacokinetics study showed that the levels of lignan were too low to be detected in rat serum even upon taking 15 times of the efective dose of lignan-rich fraction from SWH. We hypothesize that lignans from SWH might exert its bone protective efect via the gut microbiome.

**Recent Findings** Our study revealed that the lignan-rich fraction of SWH did not infuence the diversity of gut microbiota in OVX rats, but signifcantly increased the abundance of a few phyla, in particular, the restoration of the abundance of several genera that was directly correlated with bone mineral density (BMD). In addition, a subsequent metabolomic study indicated that serotonin, a neurotransmitter synthesized in the intestine and infuenced by gut microbiota, may be involved in mediating the bone protective action of the lignans. Gut-derived serotonin is thought to inhibit bone growth. Based on this fnding, several inhibitors that suppressed the synthesis of serotonin were identifed from the lignans of SWH.

**Summary** Our studies suggested that microbiome is an indispensable factor for lignans derived from *S. willimasii* to exert bone beneficial effects.

**Keyword** Osteoporosis · lignans · gut microbiota · serotonin synthesis

# **Lignans and its Role on Bone Health**

The proportion of the world's population over 60 years will be nearly double from 12 to 22% between 2015 to 2050 [\[1](#page-4-0)]. It is anticipated that 21.2% of women and 6.3% of men globally will sufer from osteoporosis and might lead to almost 70 fragility fracture per minute [[2](#page-4-1)]. Hormonal changes,

 $\boxtimes$  Man-Sau Wong man-sau.wong@polyu.edu.hk

- <sup>1</sup> Department of Food Science and Nutrients, The Hong Kong Polytechnic University, Hong Kong, China
- <sup>2</sup> Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hong Kong, China
- <sup>3</sup> State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518057, China
- <sup>4</sup> Institute of Traditional Chinese Medicine & Natural Products, Jinan University, Guangzhou, China

especially estrogen defciency associated with menopause, and aging are the major contributing factors to the pathogenesis of osteoporosis.

Phytoestrogens, which are classically defned as phytochemicals that possess similar chemical structures to endogenous estrogen, are considered to be potential alternatives to hormone replacement therapy for management of estrogen deficiency-induced symptoms in menopausal women [[3](#page-4-2)]. Lignans, one of the three major classes of phytoestrogens, are widely present in a variety of plant foods, including seeds, beans, whole grains, bran, fruits, vegetables and beverages such as tea and coffee  $[4]$  $[4]$ . Although the epidemiological studies are inconclusive, numerous health benefts have been attributed to the intake of naturally lignan-rich foods, including the reduction of risk of heart disease, menopausal symptoms, breast cancer and osteoporosis [\[3](#page-4-2), [5](#page-4-4)].

Flaxseed and sesame seeds, derived from *Linum usitatissimum L.* and *Sesamum indicium*, respectively, are the two richest known sources of lignans. The consumption of faxseed in various forms including total extract, power, flour, and oil, exhibited positive efects on bone mineral density (BMD) and bone metabolism in diferent animal models and in several clinical studies [\[6](#page-4-5)]. From 2013 to 2022, six studies reported that sesame seeds intake only, or in combination with peanut seeds or black seeds, were benefcial for improving BMD and serum bone biochemical markers in postmenopausal animal models [[7\]](#page-4-6). In contrast, a randomized, double-blind clinical trial including 199 healthy menopausal women consuming 40 flaxseed/d ( $n=101$ ) or wheat germ placebo ( $n=98$ ) for 12 months, revealed that faxseed incorporation into the diet of healthy menopausal women did not alter the BMD in lumbar or femoral neck as compared with wheat germ placebo [\[8](#page-4-7)]. Due to the limited available clinical studies, the effects of lignans on bone health are inconclusive.

# **Lignan Bioavailability and Correlation with Gut Microbiota**

Several early studies revealed that ingested lignans were deglycosylated and converted to mammalian lignans enterolactone and enterodiol by gut microbiota, absorbed into blood, fnally excreted in urine, bile and feces [[9\]](#page-4-8). Lignans such as pinoresinol, lariciresinol, secoisolariciresinol diglucoside (SDG) and matairesinol which represented four different classes of lignans were converted to enterolignans through reduction, O-deglycosylation, O-demethylation, dehydrogenation and dihydroxylation by intestine bacteria  $[10]$  $[10]$ . However, only 55%, 62% and 72% of pinoresinol diglucoside, matairesinol and SDG were converted to enterolignans, respectively $(11)$  $(11)$ . A study showed that one hour after ingestion of sesame seeds, some lignans are quickly detected in the systemic circulation, such as pinoresinol, matairesinol, lariciresinol, secoisolariciresinol and sesamin, while other studies indicated that the enterolignans generally appeared in circulation 8–10 h after intake of dietary lignans [[9\]](#page-4-8). Sacco et al. reported that after orally administering rats with trimerlabeled SDG for 7 days, 59.8% of the radioactivity, including the prototype and metabolites, was detected in the colon and cecum, while only 0.1% was detected in the entire skeletal tissue [\[12](#page-4-11)]. In addition, the fate of pure compounds does not invariably mirror the bioavailability of lignan within complex food or herbal medicines matrices. Therefore, the above publications suggest that the enterolignans or metabolites of lignans in the circulation might not be able to totally account for the benefcial actions of lignans on bone.

# **A Lignan‑Rich Herb** *Sambucus willamsii* **Hance and its Efects on Bone**

*Sambucus williamsii* Hance (SWH) belongs to *Caprifoliaceae* family and is widely distributed in China, Korea and Japan [\[13](#page-4-12)]. It is in the same genus as elderberry (also known as *Sambucus* nigra) which is popular in Europe to be used in products of syrup, gummies, soft drink, liqueur and eye gel. *S. williamsii* was frst recorded in *Tang Materia Medica* (A.D. 659) for healing fractures and alleviating pain. Our previous studies have demonstrated that the SWH extract and its lignan-rich fraction increased BMD, improved trabecular bone micro-architecture, and promoted cortical bone strength in ovariectomized mouse and rat models [[14](#page-4-13)[–17](#page-4-14)]. Fifty-six lignans were isolated and purifed in the extract of SWH and were identifed to be the bioactive components in SWH through the determination of the osteoblastic proliferation in vitro  $[18, 19]$  $[18, 19]$  $[18, 19]$  $[18, 19]$ .

#### **A Question Arises from Pharmacokinetics Study**

In order to identify the major bioavailable lignans that are associated with the bone protective efects of SWH, a pharmacokinetic study using rat model was carried out. The rats were administrated with an efective dose or a 15-times efective dose of the SWH fraction, followed by collection of the blood samples at 0, 5, 15, 30, 60, 120, 180, 240, 360, and 480 min. However, neither the prototype nor metabolites were detected by highly sensitive method using an ultrahigh performance liquid chromatography with quadrupole time-of-fight mass spectrometry (UPLC-QTOF/MS). To accumulate sufficient exogenous components in blood, samples were again collected and analyzed from rats gavaged daily with effective dose or 15-times effective dose of SWH fraction for 3 days. However, no detectable prototype nor metabolites of lignans could be detected in serum collected from these rats treated with SWH fraction for 3 days. The in-house results indicated that lignan-rich fraction may be composed of too many lignans with too low concentration of each type of lignan to be detected in blood. However, the lack of detectable lignans in the circulation might also suggest that mechanisms that do not require gastrointestinal uptake of lignans might be involved. This unsuccessful pharmacokinetic study prompted us to explore other mechanisms that might account for the bone protective efects of lignans.

#### **Gut Microbiome Interaction with Lignan**

Based on the fact that the bone protective efects of SWH was demonstrated in response to its oral administration, we hypothesized that lignans from SWH might exert its bone protective efect via the gut microbiome, including gut microbiota, their metabolites and their living environment [[20](#page-4-17)]. An animal study using the lignan-rich fraction (CA) from SWH was performed to test the hypothesis [\[21](#page-4-18)]. Female SD rats (4-month old) were sham operated or ovariectomized, and treated with vehicle, PTH (1.8 µg/kg,  $n=8$ , intramuscularly injected), CA (140 mg/kg,  $n=10$ ) for 10 weeks. The results exhibited that the lignan-rich fraction from SWH at 140 mg/kg prevented the reduction in BMD at distal femur and proximal tibia and improved bone microarchitecture in OVX rats, and these efects were similar to those of PTH on the trabecular bone.

The 16S rRNA sequencing of fecal samples showed that the microbial diversities of all groups increased signifcantly upon 10 weeks of treatment when compared to OVX group at 0 week, while no signifcant diferences were found among the Sham, OVX and CA groups at week 10. The Principal Coordinate analysis (PCoA) and Partial least squares discriminant analysis (PLS-DA) analysis showed that the operational taxonomic units (OTUs) at week 10 were well separated from that at week 0, suggesting the microbial composition had altered over time. At week 10, the bacteria in the CA treatment group induced a signifcant separation from that of the Sham and OVX groups, indicating that CA treatment had signifcant infuence on intestinal bacterial composition.

The difference analysis between groups and the LEfSe (linear discriminant analysis Effect Size) analysis showed that the abundance of *Antinobacteria* phylum extremely enriched in OVX rat fecal samples in response to CA treatment, and the taxa contributed to the abundance included: class, *Antinobacteria*; order, *Coriobacteriales*; family, *Coriobacteriacene*; genus, *Adlercreutzia*, norank\_f\_*Coriobacteriaceae*, *Parvibacter*, *Enterorhabdus*, *Collinsella*. The fve genera belonged to *Antinobacteria* phylum were signifcantly reversed in the OVX rats treated with CA when compared with the OVX groups. These altered genera are related to the production of short chain fatty acid, modifcation of host bile acids and cholesterol levels, low dietary fber intake and circulating insulin, cholesterol absorption, synthesis, and excretion [[21](#page-4-18)]. Further spearman's correlation analysis revealed that BMD was directly correlated with several genera, such as *Lachnospiraceae\_ NK4A136\_group* and *[Eubacterium] coprostanoligenes group,* which are related to tryptophan metabolism. The results indicated that CA treatment might indirectly afect bone metabolism via modifying the metabolism of tryptophan in the gut.

#### **Serotonin Involved in the Actions of Lignans on Bone**

A metabolomic study was performed to identify if tryptophan metabolism was involved in the actions of lignans on bone. The resulted showed that tryptophan level in OVX rats was signifcantly restored upon treatment with the lignanrich fraction of SWH for 12 weeks [\[17](#page-4-14)]. Tryptophan has two major catabolic pathways, the kynurenine (Kyn) pathway and serotonin (5-HT) pathway. The serum kynurenine level and serotonin level upon treatment with CA were quantifed using an ultra-performance liquid chromatography tandem triple quadrupole mass spectrometry (UPLC-TQD-MS) method. The results showed that CA treatment signifcantly reduced serum 5-HT level, but not Kyn level, in OVX rats. The linear regression analysis showed that BMD was negatively correlated to serum 5-HT in rats [[21](#page-4-18)].

Serotonin is best known as a neurotransmitter, and more than 90% of the body's serotonin is synthesized by enterochromafn cells in intestine, while the others is synthesized by clusters of neurons in brain. As serotonin cannot pass through the blood–brain barrier, all serotonin in the circulatory system comes from intestine. Tryptophan hydroxylase (TPH) is the rate-limiting enzyme of 5-HT biosynthesis, and only the subtype of TPH-1 is located in the intestine, while the subtypes of TPH-1 and TPH-2 are distributed in the brain [\[22](#page-4-19)]. Our studies showed that CA signifcantly suppressed the protein expression of TPH-1 in the colon, while did not alter the protein expressions of TPH-1 and TPH-2 in cerebral cortex in OVX rats.

For the serotonin signaling pathway in osteoblast, the gutderived 5-HT is delivered to osteoblasts by platelets, and its binding to the membrane 5HT1b receptor will then trigger the FOXO1/CRBE and FOXO1/ATF4 signaling cascade in osteoblastic cells. When high level of 5-HT acts on osteoblasts, the balance between FOXO1/CRBE and FOXO1/ ATF4 will be broken and lead to the decrease in bone formation [\[23\]](#page-4-20). In our study, the mRNA and protein expressions of CREB in femur were not altered by OVX nor CA treatment. In contrast mRNA and protein expressions of ATF4 and FOXO1 in femur were signifcantly upregulated and downregulated in OVX rats, respectively; and these changes were signifcantly reversed in OVX rats in response to treatment with CA [\[21](#page-4-18)].

Taken together, our study clearly demonstrated that the lignan-rich fraction derived from *Sambucus williamsii* Hance exerted bone protective effects via altering circulating serotonin and gut microbiota.

#### **Exploring a Novel Class of TPH‑1 Inhibitor**

Based on our discovery of the involvement of TPH-1 and serotonin in mediating the actions of lignan-rich fraction of SWH, subsequent study to identify TPH-1 inhibitors from SWH was performed  $[24]$  $[24]$ . The binding affinities of lignans isolated and purifed from SWH were determined by molecular docking and surface plasmon resonance (SPR), the protein activity and expression of TPH-1 was tested in vitro, and serum serotonin level and BMD in mice upon treatment with purifed lignan compound were measured. Our results showed that lignans derived from SWH exhibited high binding affinities to the TPH-1 protein, inhibited the activity and expression of TPH-1 in RBL2H3 cells, the *Tph-1* gene highexpressing cells, and suppressed serum serotonin levels as well as signifcantly improved BMD in OVX mice. A series of novel class TPH-1 inhibitors, the lignans derived from SWH, were explored. The results provided the direct evidence that lignans could act on TPH-1 and infuence serotonin synthesis and its circulating levels, thereby indirectly modulate bone metabolism in OVX animal model.

# **Conclusion**

The mechanism of actions of lignan derived from SWH were summarized in Fig. [1.](#page-3-0) In conclusion, lignans appear to exert protective efects on bone by modulating the composition of microbiota and suppressing the synthesis of gut-derived serotonin, without the need to be absorbed into the circulation. Microbiome, including microbiota, their metabolites and their living environment, is an indispensable factor for lignans to exert bone beneficial effects.

# **Key References**

• International Osteoporosis Foundation. Epidemiology of osteoporosis and fragility fractures. [https://www.osteo](https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures) [porosis.foundation/facts-statistics/epidemiology-of-osteo](https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures) [porosis-and-fragility-fractures](https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures): International Osteoporosis Foundation. 2024.

Overview the latest epidemiology of osteoporosis and fragility fractures worldwide, along with the burden and impact of hip fractures and vertebral fractures, and outlined the rate of fractures caused by falls and the risk of secondary fractures.

• Batool I, Altemimi AB, Munir S, Imran S, Khalid N, Khan MA, et al. Exploring faxseed's potential in enhancing bone health: Unveiling osteo-protective properties. Journal of agriculture and food research 2024; 15: 101,018.

Comprehensive overview of the bone protective efficacy of flaxseed in different forms like oil, flour, extract and powder in preclinical experiments and clinical trials, and revealed the mechanism of promoting bone health and density by unsaturated fatty acid, lignans and fber in faxseeds.

• Arooj A, Rabail R, Naeem M, Goksen G, Xu B, Aadil RM. A comprehensive review of the bioactive components of sesame seeds and their impact on bone health issues in postmenopausal women. Food Funct 2023;14(11):4966–498.

Good summary of the positive role of sesame seeds on bone health in postmenopausal women and animal models, and the nutritional composition and bioac-



<span id="page-3-0"></span>**Fig. 1** The action scheme of lignan-rich fraction derived from *Sambucus williamsii* Hance one bone

tive ingredients of sesame seeds. Supported the use of sesame seeds as supplements in regular diet.

**Author Contributions** H.-H.X. wrote the main text and prepared Fig. 1. M.-S.W., D.K.-W.M. and X.-S.Y. designed the study and supervised the experiments. All authors reviewed the manuscript and have agreed to the published version of the manuscript.

**Funding** Open access funding provided by The Hong Kong Polytechnic University. This work was supported by the The Hong Kong Midstream Research Programme for Universities (MRP/012/18X), Mainland-Hong Kong Joint Funding Scheme (ITF-MOST: MHX/002/20), PolyU Project of Strategic Importance (ZE2G), Natural Science Foundation of Guangdong Province (2021A1515010648) and the National Natural Science Foundation of China (81903616).

**Data Availability** No datasets were generated or analysed during the current study.

#### **Declarations**

**Competing Interests** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

### **References**

- <span id="page-4-0"></span>1. World Health Organization. Aging and health. 2022. [https://www.](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health) [who.int/news-room/fact-sheets/detail/ageing-and-health:](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health) World Health Organization. Accessed 24 Apr 2024.
- <span id="page-4-1"></span>2. International Osteoporosis Foundation. Epidemiology of osteoporosis and fragility fractures. 2024. [https://www.osteoporosis.foundation/](https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures) [facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures:](https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures) International Osteoporosis Foundation. Accessed 24 Apr 2024.
- <span id="page-4-2"></span>3. Domínguez-López I, Yago-Aragón M, Salas-Huetos A, Tresserra-Rimbau A, Hurtado-Barroso S. Efects of dietary phytoestrogens on hormones throughout a human lifespan: a review. Nutrients. 2020;12(8):2456.
- <span id="page-4-3"></span>4. Cione E, La Torre C, Cannataro R, Caroleo MC, Plastina P, Gallelli L. Quercetin, epigallocatechin gallate, curcumin, and resveratrol: from dietary sources to human MicroRNA modulation. Molecules. 2019;25(1):63.
- <span id="page-4-4"></span>5. Rodríguez-García C, Sánchez-Quesada C, Toledo E, Delgado-Rodríguez M, Gaforio JJ. Naturally lignan-rich foods: a dietary tool for health promotion? Molecules. 2019;24(5):917.
- <span id="page-4-5"></span>6. Batool I, Altemimi AB, Munir S, Imran S, Khalid N, Khan MA, et al. Exploring flaxseed's potential in enhancing bone health: unveiling osteo-protective properties. J Agric Food Res. 2024;15:101018.
- <span id="page-4-6"></span>7. Arooj A, Rabail R, Naeem M, Goksen G, Xu B, Aadil RM. A comprehensive review of the bioactive components of sesame seeds and their impact on bone health issues in postmenopausal women. Food Funct. 2023;14(11):4966–5498.
- <span id="page-4-7"></span>8. Dodin S, Lemay A, Jacques H, Légaré F, Forest JC, Masse B. The efects of faxseed dietary supplement on lipid profle, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005;90(3):1390–7.
- <span id="page-4-8"></span>9. Soleymani S, Habtemariam S, Rahimi R, Nabavi SM. The what and who of dietary lignans in human health: Special focus on prooxidant and antioxidant efects. Trends Food Sci Technol. 2020;106:382–90.
- <span id="page-4-9"></span>10. Clavel T, Doré J, Blaut M. Bioavailability of lignans in human subjects. Nutr Res Rev. 2006;19(2):187–96.
- <span id="page-4-10"></span>11. Peterson J, Dwyer J, Adlercreutz H, Scalbert A, Jacques P, McCullough ML. Dietary lignans: physiology and potential for cardiovascular disease risk reduction. Nutr Rev. 2010;68(10):571–603.
- <span id="page-4-11"></span>12. Sacco SM, Thompson LU, Ganss B, Ward WE. Accessibility of 3H-Secoisolariciresinol diglycoside Lignan metabolites in skeletal tissue of ovariectomized rats. J Med Food. 2011;14(10):1208–14.
- <span id="page-4-12"></span>13. Lei X, Zhang Y, Wei X, Tang Y, Qu Q, Zhao X, et al. Sambucus williamsii Hance: a comprehensive review of traditional uses, processing specifcations, botany, phytochemistry, pharmacology, toxicology, and pharmacokinetics. J Ethnopharmacol. 2024;326:117940.
- <span id="page-4-13"></span>14. Xie F, Wu CF, Zhang Y, Yao XS, Cheung PY, Chan AS, et al. Increase in bone mass and bone strength by *Sambucus williamsii* HANCE. Biol Pharm Bull. 2005;28(10):1879–85.
- 15. Zhang Y, Li Q, Wan HY, Xiao HH, Lai WP, Yao XS, et al. Study of the mechanisms by which *Sambucus williamsii* HANCE extract exert protective efects aginst ovariectomy-induced osteoporosis *in vivo*. Osteoporos Int. 2011;22(2):703–9.
- 16. Xiao HH, Dai Y, Wan HY, Wong MS, Yao XS. Bone protective efects of bioactive fractions and ingredients in *Sambucus williamsii* HANCE. Br J Nutr. 2011;106(12):1802–9.
- <span id="page-4-14"></span>17 Xiao HH, Sham TT, Chan CO, Li MH, Chen X, Wu QC, et al. A metabolomics study on the bone protective efects of a lignan-rich fraction from Sambucus Williamsii Ramulus in aged rats. Front Pharmacol. 2018;9:932.
- <span id="page-4-15"></span>18. Xiao HH, Dai Y, Wong MS, Yao XS. New lignans from the bioactive fraction of *Sambucus williamsii* Hance and proliferation activities on osteoblastic-like UMR106 cells. Fitoterapia. 2014;94C:29–35.
- <span id="page-4-16"></span>19. Xiao HH, Lv J, Mok D, Yao XS, Wong MS, Cooper R. NMR applications for botanical mixtures: the use of HSQC data to determine lignan content in Sambucus williamsii. J Nat Prod. 2019;82(7):1733–40.
- <span id="page-4-17"></span>20. Berg G, Rybakova D, Fischer D, Cernava T, Vergès MC, Charles T, et al. Microbiome defnition re-visited: old concepts and new challenges. Microbiome. 2020;8(1):103.
- <span id="page-4-18"></span>21. Xiao HH, Zhu YX, Lu L, Zhou LP, Poon CCW, Chan CO, et al. The lignan-rich fraction from Sambucus williamsii Hance exerts bone protective efects via altering circulating serotonin and gut microbiota in rats. Nutrients. 2022;14:4718.
- <span id="page-4-19"></span>22. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;163(1):258.
- <span id="page-4-20"></span>23. Lavoie B, Lian JB, Mawe GM. Regulation of bone metabolism by serotonin. Adv Exp Med Biol. 2017;1033:35–46.
- <span id="page-4-21"></span>24. Zhu YX, Tang ZL, Lu L, Qiu ZC, Pan DB, Yu Y, et al. Exploring a novel class tryptophan hydroxylase 1 inhibitor derived from *Sambucus williamsii* Hance for the osteoporosis treatment. Acupunct Herbal Med. 2024;4(1):102–12.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.